Literature DB >> 25031716

Distinct patterns of ALDH1A1 expression predict metastasis and poor outcome of colorectal carcinoma.

Sen-Lin Xu1, Dong-Zu Zeng2, Wei-Guo Dong3, Yan-Qing Ding4, Jun Rao5, Jiang-Jie Duan1, Qing Liu1, Jing Yang1, Na Zhan6, Ying Liu1, Qi-Ping Hu1, Xia Zhang1, You-Hong Cui1, Hsiang-Fu Kung1, Shi-Cang Yu1, Xiu-Wu Bian1.   

Abstract

PURPOSE: Aldehyde dehydrogenase 1A1 (ALDH1A1) has been proposed as a candidate biomarker for colorectal carcinoma (CRC). However, the heterogeneity of its expression makes it difficult to predict the outcome of CRC. The aim of this study was to evaluate the diagnostic and prognostic value of this molecule in CRC. METHODS AND
RESULTS: In this study, we examined ALDH1A1 expression by immunohistochemistry including 406 cases of primary CRC with corresponding adjacent mucosa, with confirmation of real-time PCR and Western blotting. We found that the expression patterns of ALDH1A1 were heterogeneous in the CRC and corresponding adjacent tissues. We defined the ratio of ALDH1A1 level in adjacent mucosa to that in tumor tissues as RA/C and found that the capabilities of tumor invasion and metastasis in the tumors with RA/C < 1 were significantly higher than those with RA/C ≥ 1. Follow-up data showed the worse prognoses in the CRC patients with RA/C < 1. For understanding the underlying mechanism, the localization of β-catenin was detected in the CRC tissues with different patterns of ALDH1A1 expression from 221 patients and β-catenin was found preferentially expressed in cell nuclei of the tumors with RA/C < 1 and ALDH1A1(high) expression of HT29 cell line, indicating that nuclear translocation of β-catenin might contribute to the increased potentials of invasion and metastasis.
CONCLUSION: Our results indicate that RA/C is a novel biomarker to reflect the distinct expression patterns of ALDH1A1 for predicting metastasis and prognosis of CRC.

Entities:  

Keywords:  Colorectal carcinoma; aldehyde dehydrogenase 1A1; metastasis; prognosis; β-catenin

Mesh:

Substances:

Year:  2014        PMID: 25031716      PMCID: PMC4097282     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  37 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  Retinol decreases beta-catenin protein levels in retinoic acid-resistant colon cancer cell lines.

Authors:  Alice C Dillard; Michelle A Lane
Journal:  Mol Carcinog       Date:  2007-04       Impact factor: 4.784

3.  Apc modulates embryonic stem-cell differentiation by controlling the dosage of beta-catenin signaling.

Authors:  Menno F Kielman; Maaret Rindapää; Claudia Gaspar; Nicole van Poppel; Cor Breukel; Sandra van Leeuwen; Makoto Mark Taketo; Scott Roberts; Ron Smits; Riccardo Fodde
Journal:  Nat Genet       Date:  2002-11-11       Impact factor: 38.330

4.  β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness.

Authors:  Ester Sánchez-Tilló; Oriol de Barrios; Laura Siles; Miriam Cuatrecasas; Antoni Castells; Antonio Postigo
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-11       Impact factor: 11.205

5.  Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs.

Authors:  Desheng Lu; Howard B Cottam; Maripat Corr; Dennis A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-13       Impact factor: 11.205

6.  Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers.

Authors:  Shan Deng; Xiaojun Yang; Heini Lassus; Shun Liang; Sippy Kaur; Qunrui Ye; Chunsheng Li; Li-Ping Wang; Katherine F Roby; Sandra Orsulic; Denise C Connolly; Youcheng Zhang; Kathleen Montone; Ralf Bützow; George Coukos; Lin Zhang
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

7.  CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer.

Authors:  David Horst; Lydia Kriegl; Jutta Engel; Andreas Jung; Thomas Kirchner
Journal:  Eur J Cancer       Date:  2009-05-04       Impact factor: 9.162

8.  Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis.

Authors:  Emina H Huang; Mark J Hynes; Tao Zhang; Christophe Ginestier; Gabriela Dontu; Henry Appelman; Jeremy Z Fields; Max S Wicha; Bruce M Boman
Journal:  Cancer Res       Date:  2009-03-31       Impact factor: 12.701

9.  Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression.

Authors:  Fieke E M Froeling; Christine Feig; Claude Chelala; Richard Dobson; Charles E Mein; David A Tuveson; Hans Clevers; Ian R Hart; Hemant M Kocher
Journal:  Gastroenterology       Date:  2011-06-24       Impact factor: 22.682

10.  Low expression of LOC285194 is associated with poor prognosis in colorectal cancer.

Authors:  Peng Qi; Mi-die Xu; Shu-juan Ni; Dan Huang; Ping Wei; Cong Tan; Xiao-yan Zhou; Xiang Du
Journal:  J Transl Med       Date:  2013-05-16       Impact factor: 5.531

View more
  16 in total

1.  Distinct prognostic values of ALDH1 isoenzymes in breast cancer.

Authors:  Shaokun Wu; Weiping Xue; Xiaobo Huang; Xiaoli Yu; Ming Luo; Ying Huang; Yimin Liu; Zhuofei Bi; Xingsheng Qiu; Shoumin Bai
Journal:  Tumour Biol       Date:  2015-01-13

2.  Evaluation of the Role of ALDH1 as Cancer Stem Cell Marker in Colorectal Carcinoma: An Immunohistochemical Study.

Authors:  Nanis Shawky Holah; Hayam Abd-El-Samie Aiad; Nancy Yousif Asaad; Enas Abobakr Elkhouly; Ayat Gamal Lasheen
Journal:  J Clin Diagn Res       Date:  2017-01-01

Review 3.  ALDH1A1 in Cancers: Bidirectional Function, Drug Resistance, and Regulatory Mechanism.

Authors:  Hanxun Yue; Zenan Hu; Rui Hu; Zeying Guo; Ya Zheng; Yuping Wang; Yongning Zhou
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

4.  Peritoneal expression of Matrilysin helps identify early post-operative recurrence of colorectal cancer.

Authors:  Giuseppe S Sica; Cristina Fiorani; Carmine Stolfi; Giovanni Monteleone; Eleonora Candi; Ivano Amelio; Valeria Catani; Simone Sibio; Andrea Divizia; Giorgia Tema; Edoardo Iaculli; Achille L Gaspari
Journal:  Oncotarget       Date:  2015-05-30

5.  ALDH1A1-overexpressing cells are differentiated cells but not cancer stem or progenitor cells in human hepatocellular carcinoma.

Authors:  Kaori Tanaka; Hiroyuki Tomita; Kenji Hisamatsu; Takayuki Nakashima; Yuichiro Hatano; Yoshiyuki Sasaki; Shinji Osada; Takuji Tanaka; Tatsuhiko Miyazaki; Kazuhiro Yoshida; Akira Hara
Journal:  Oncotarget       Date:  2015-09-22

6.  Complex Behavior of ALDH1A1 and IGFBP1 in Liver Metastasis from a Colorectal Cancer.

Authors:  Jin Cheon Kim; Ye Jin Ha; Ka Hee Tak; Seon Ae Roh; Chan Wook Kim; Tae Won Kim; Seon-Kyu Kim; Seon-Young Kim; Dong-Hyung Cho; Yong Sung Kim
Journal:  PLoS One       Date:  2016-05-06       Impact factor: 3.240

7.  The prognostic roles of ALDH1 isoenzymes in gastric cancer.

Authors:  Kai Li; Xiaoguang Guo; Ziwei Wang; Xiaofeng Li; Youquan Bu; Xuefeng Bai; Liansheng Zheng; Ying Huang
Journal:  Onco Targets Ther       Date:  2016-06-07       Impact factor: 4.147

8.  A High-Content Assay Enables the Automated Screening and Identification of Small Molecules with Specific ALDH1A1-Inhibitory Activity.

Authors:  Adam Yasgar; Steven A Titus; Yuhong Wang; Carina Danchik; Shyh-Ming Yang; Vasilis Vasiliou; Ajit Jadhav; David J Maloney; Anton Simeonov; Natalia J Martinez
Journal:  PLoS One       Date:  2017-01-27       Impact factor: 3.240

9.  Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer.

Authors:  Qinghua You; Huanchen Guo; Dongxiang Xu
Journal:  Drug Des Devel Ther       Date:  2015-09-03       Impact factor: 4.162

10.  Prognostic values of aldehyde dehydrogenase 1 isoenzymes in ovarian cancer.

Authors:  Yu-Mei Ma; Shan Zhao
Journal:  Onco Targets Ther       Date:  2016-04-04       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.